A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations
Condition(s) studied
Investigational drug(s) / intervention(s)
relatlimab+nivolumab: Specified dose on specified days
relatlimab+nivolumab+rHuPH20: Specified dose on specified days
nivolumab: Specified dose on specified days
nivolumab+rHuPH20: Specified dose on specified days
Study summary
The purpose of this study is to assess the patient's preference for nivolumab subcutaneous (SC) or nivolumab + relatlimab fixed-dose combination (FDC) SC and provide patient experience data by route of administration. This study will also generate safety data which will further characterize the safety profile of patients switching the route of administration from intravenous (IV) to SC.
Eligibility
Primary outcome measure(s)
- Percentage of Evaluable Participants That Prefer SC Route of Administration Using the Patient Experience and Preference Questionnaire (PEPQ) (Question 7) After Cycle 4 Day 1 Dose — Cycle 4 Day 1 (each cycle consist of 4 weeks)
PEPQ included 7 items 1. Pain or Discomfort (rated on 1 to 10 scale), 2. Length of time related to administration 3. Length of time related to administration impact amount of time to speak to doctor or nurse about illness or concern 4. Length of time for administration impact time to interact or socialize with other individuals 5. Convenience 6. Satisfaction 7. Choice of which route of administration would be preferred. 95% CI exact confidence interval was reported.
Trial sites (31)
| Facility | City | Region | Status |
|---|---|---|---|
| Local Institution - 0007 | Anchorage | Alaska | |
| Local Institution - 0013 | Phoenix | Arizona | |
| Local Institution - 0010 | San Francisco | California | |
| Local Institution - 0034 | Atlanta | Georgia | |
| Local Institution - 0032 | Edgewood | Kentucky | |
| Local Institution - 0028 | Albuquerque | New Mexico | |
| Local Institution - 0037 | Edmonds | Washington | |
| Local Institution - 0036 | Issaquah | Washington | |
| Local Institution - 0030 | Seattle | Washington | |
| Local Institution - 0015 | Las Condes | Santiago Metropolitan | |
| Local Institution - 0005 | Concepción | Chile | |
| Local Institution - 0019 | Thessaloniki | B | |
| Local Institution - 0014 | Athens | I | |
| Local Institution - 0029 | Marousi | I | |
| Local Institution - 0023 | Holargos, Athens | Greece | |
| Local Institution - 0008 | Piraeus | Greece | |
| Local Institution - 0033 | Thessaloniki | Greece | |
| Local Institution - 0017 | Bergamo | BG | |
| Local Institution - 0035 | Meldola | FC | |
| Local Institution - 0018 | Milan | MI | |
| Local Institution - 0012 | Padova | PD | |
| Local Institution - 0021 | Roma | RM | |
| Local Institution - 0004 | Torino | TO | |
| Local Institution - 0026 | Naples | Italy | |
| Local Institution - 0011 | Barcelona | B | |
| Local Institution - 0022 | Barcelona | B | |
| Local Institution - 0009 | Cartagena | MU | |
| Local Institution - 0020 | Badalona | Spain | |
| Local Institution - 0027 | Cantabria | Spain | |
| Local Institution - 0003 | San Pedro Alcántara, Málaga | Spain | |
| Local Institution - 0006 | Seville | Spain |
On this site
📄 Opdivo (nivolumab) drug profile →More Bristol-Myers Squibb trials in Spain
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06101134 on ClinicalTrials.gov ↗ ← All trials in Spain